Resources

Proteomics Databases



Metabolomics Databases

• • Phage Immunoprecipitation Sequencing Service: How PhIP-Seq Profiles Antibody-Peptide Binding

  A phage immunoprecipitation sequencing (PhIP-Seq) service profiles antibody-peptide binding by capturing antibody-bound, phage-displayed peptides and measuring which library members become enriched by sequencing.

• • From Transition Pairs to Quantitative Assays: Multiple Reaction Monitoring for Targeted Peptide Quantification

  Multiple reaction monitoring (MRM), also called selected reaction monitoring (SRM) on some triple-quadrupole platforms, answers that question by measuring predefined precursor-to- product ion transitions for target peptides. The mass spectrometer selects a specific peptide ion in the first quadrupole (Q1), fragments it in the collision cell (Q2), and monitors one or more product ions in the third quadrupole (Q3).

• • What Determines N-Terminal Sequencing Cost? Sample Purity, Method Choice, and Sequence Length

  Researchers planning N-terminal sequencing often ask for a single price before the sample and reporting goal are defined. That question is understandable. Grant budgets, vendor comparisons, and QC timelines all depend on cost predictability. However, terminal analysis is rarely sold as a fixed-price assay.

• • N-Terminal Sequencing Methods Compared: Edman Degradation vs Mass Spectrometry

  Researchers who need N-terminal evidence often begin with a simple assumption: one assay should read the first residues and answer the question. In practice, the main N-terminal sequencing methods split into two major routes. Sequential Edman chemistry reads the protein terminus directly, one residue per cycle. MS-based approaches infer terminal sequence through intact mass measurement, terminal peptide identification, or LC-MS/MS analysis of selected fragments.

• • How to Choose an N-Terminal Sequencing Strategy for Recombinant Proteins and Unknown Bands

  N-terminal sequence questions often arrive in two very different forms. A recombinant protein team may need to confirm that a secretion leader, affinity tag, or propeptide was removed as designed. A discovery team may instead face an unknown protein band on SDS-PAGE and need the first residues to guide identification, cloning, or follow-up proteomics.

• • What Is Mass Spectrometry-Based Histone Succinylation Analysis?

  Histone succinylation (Ksucc), as an emerging epigenetic modification, has attracted considerable attention in life science research in recent years. It not only reflects dynamic changes in chromatin architecture but also provides insight into cellular metabolic states and disease mechanisms. Mass spectrometry has therefore become a core analytical tool for investigating histone succinylation. Scientific Background of Histone Succinylation 1. Chemical Characteristics and Mechanisms of Action Histone ......

• • What Is Protein Terminal Sequencing?

  Protein terminal sequencing is a critical analytical approach for characterizing the amino-terminal (N-terminus) and carboxyl-terminal (C-terminus) sequences of proteins, playing an essential role in understanding protein structure, biological function, and post-translational modifications. Terminal sequences not only influence protein spatial folding and molecular interaction capabilities, but also reflect maturation status and post-translational processing events. Through terminal sequencing, resear......

• • What Is Antibody Glycosylation?

  Learn what antibody glycosylation is, where glycans attach on IgG molecules, and why Fc glycosylation matters for antibody heterogeneity and characterization.

• • Top-Down vs. Bottom-Up Proteomics: Key Differences and When to Use Each

  Compare top-down and bottom-up proteomics by structural resolution, sample complexity, proteoform context, and project fit for discovery, biologics, and proteoform analysis workflows.

• • Step-by-Step LC-MS Peptide Mapping

  Follow a practical LC-MS peptide mapping workflow from sample preparation through digestion, LC-MS/MS analysis, database search, and coverage reporting for biologics characterization.